Zoetis Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Zoetis Inc. (ZTS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $85.26 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-12
- Zoetis Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $85.26, a 31.53% increase from fiscal 2024.
- Zoetis Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $64.82, a 8.23% increase from fiscal 2023.
- Zoetis Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $59.89, a 4.89% increase from fiscal 2022.
- Zoetis Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $57.10, a 7.98% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|
| 2025-12-31 | $85.26 10-K · filed 2026-02-12 | |
| 2024-12-31 | $64.82 10-K · filed 2025-02-13 | |
| 2023-12-31 | $59.89 10-K · filed 2024-02-13 | |
| 2022-12-31 | $57.10 10-K · filed 2023-02-14 | |
| 2021-12-31 | $52.88 10-K · filed 2022-02-15 | |
| 2020-12-31 | $47.80 10-K · filed 2021-02-16 | |
| 2019-12-31 | $35.32 10-K · filed 2020-02-13 | |
| 2018-12-31 | $30.38 10-K · filed 2019-02-14 | |
| 2017-12-31 | $30.18 10-K · filed 2018-02-15 | |
| 2016-12-31 | $28.54 10-K · filed 2017-02-16 | |
| 2015-12-31 | $28.99 10-K · filed 2016-02-24 | |
| 2014-12-31 | $26.00 10-K · filed 2015-02-27 | |
| 2013-12-31 | $26.00 10-K · filed 2014-03-26 | |
| 2013-09-29 | $26.00 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |